Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by wyndeweston Jul 25, 2018 9:56am
208 Views
Post# 28363981

RE:RE:bio you seem very happy with the way pl and board

RE:RE:bio you seem very happy with the way pl and boardInteresting post Biofinder, especially the bit about the FDA playing Prometic.  It does seem every time the FDA weighs in on their BIoScience objectives, PLI falls in line line with their ideas/plans.  Sometimes, I think their statements/iplans are being made because of PLI.  As you said, I'm sure there will be a large facility opened in the USA. One of the fallouts of this new BioScience disruptive technology will be the well paid lobbyists who will try to stop it on behalf of existing approved drugs (companies). It think the FDA is preparing for this scenario as well.  The next few years are going to be interesting. GLTA longs.
Bullboard Posts